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• How best to quantify thrombosis risk with peripherally inserted central 
catheters (PICC) is unknown. 
Essentials 
• Data from a registry was used to develop the Michigan Risk Score (MRS) 
for PICC thrombosis. • Five risk factors were associated with PICC thrombosis and used to 
develop a risk score. • MRS was predictive of the risk of PICC thrombosis and can be useful in 
practice.  
ABSTRACT 
BACKGROUND: Peripherally inserted central catheters (PICCs) are associated with 
upper extremity deep vein thrombosis (DVT). We developed a score to predict 
risk of PICC-related thrombosis. 
 
METHODS: Using data from the Michigan Hospital Medicine Safety consortium, 
image-confirmed upper-extremity DVT cases were identified. A logistic, mixed 
effects model with hospital-specific random intercepts was used to identify 
factors associated with PICC-DVT. Points were assigned to each predictor, 
stratifying patients into four classes of risk. Internal validation was performed by 
bootstrapping with assessment of calibration and discrimination of the model. 
 
RESULTS: Of 23,010 patients who received PICCs, 475 (2.1%) developed 
symptomatic PICC-DVT. Risk factors associated with PICC-DVT included: 
history of DVT; multi-lumen PICC; active cancer; presence of another CVC when 
the PICC was placed; and white blood cell count greater than 12,000. 
Thrombosis rates were 0.9% for class I, 1.6% for class II, 2.7% for class III and 
4.7% for class IV, with marginal predicted probabilities of 0.9% (0.7, 1.2), 1.5% 
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(1.2, 1.9), 2.6% (2.2, 3.0) and 4.5% (3.7, 5.4) for classes I, II, III, IV and V, 
respectively. The risk classification rule was associated with PICC-DVT, with 
odds ratios of 1.68 (95 % CI: 1.19, 2.37), 2.90 (95 % CI: 2.09, 4.01) and 5.20 (95 
% CI: 3.65, 7.42) for risk classes II, III and IV vs. risk class I, respectively.  
 
CONCLUSION: The Michigan PICC-DVT Risk Score offers a novel way to estimate 
risk of DVT associated with PICCs and can help inform appropriateness of PICC 
insertion.  
Keywords: thrombosis, venous thromboembolism, deep vein thrombosis, 
peripherally inserted central catheter, upper extremity 
 
INTRODUCTION 
 Although infrequent, approximately three-quarters of upper-extremity deep 
vein thrombosis (DVT) are associated with indwelling vascular catheters.[1, 2] 
This association is not surprising; catheter insertion leads to endothelial damage, 
occupies the vein lumen promoting venous stasis, and is often required in 
patients with hypercoagulability due to intercurrent illness or malignancy. Thus, 
placement of these devices satisfies Virchow's triad, leading to increased risk of 
venous thromboembolism (VTE).   
 Owing to ease of insertion and growing availability of vascular access 
teams, peripherally inserted central catheters (PICCs) have become among the 
most common type of central venous catheter inserted in hospitalized patients. 
Growing use of PICCs has led to the recognition that they are strongly 
associated with VTE.[3-5] In a meta-analysis of 62 studies, (including 12 directly 
comparing patients that received PICCs to those that received conventional 
catheters), PICCs were associated with 2.5-fold greater risk of DVT than 
traditional central venous catheters.[6] Notably, the magnitude of PICC-DVT was 
greater among patients with cancer and critical illness, populations that receive 
PICCs for life-saving treatments.[7, 8] Additionally, PICC-DVT is by no means 
rare in general medical patients; a single site case-cohort study reported a 13-
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fold greater risk of thrombosis in patients that received PICCs across all medical 
sub-specialties.[9] 
 Given the clinical significance of thrombosis associated with PICCs, a tool 
with which to classify DVT risk could be helpful in several ways. First, it could 
help identify patients at greater risk of this complication, thus informing the risk of 
PICC use prior to placement. Second, a risk scoring tool may inform testing, such 
as adopting a lower threshold for patients deemed high-risk with few or vague 
symptoms. Finally, such a tool might also inform duration and intensity of 
anticoagulation in patients who experience thrombosis, with consideration of 
extended courses for certain subgroups. In this study, we developed the 
Michigan Risk Score to estimate and calculate risk of thrombosis related to 
PICCs in medical patients admitted to general wards or intensive care unit 
settings. 
 
METHODS 
Study Setting and Participants 
 The study was conducted using data from the Michigan Hospital Medicine 
Safety (HMS) consortium, a 51-hospital collaborative quality initiative supported 
by Blue Cross Blue Shield of Michigan and Blue Care Network. The design and 
setting of this consortium have been previously described.[10-12] In brief, HMS 
hospitals have been prospectively collecting data regarding PICC use and 
outcomes.[3] Adult patients admitted to a general medicine ward or intensive 
care unit (ICU) of a participating hospital who receive a PICC for any reason 
during clinical care are eligible for inclusion. Patients who are (a) under the age 
of 18; (b) pregnant; (c) admitted to a non-medical service (e.g., general surgery); 
or (d) admitted under observation status are excluded.  
 At each hospital, dedicated, trained medical record abstractors use a 
standardized protocol to collect clinical data directly from health records of 
patients. Patients with PICCs are sampled on a 14-day cycle, and data from the 
first 17 cases that meet eligibility criteria within each cycle is collected. To ensure 
adequate representation of critically ill patients, we ask sites to ensure that 7 of 
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the 17 eligible cases include PICC placement in an ICU-setting. All patients are 
followed until PICC removal, death, or 70-days, whichever occurs first. To ensure 
completeness and accuracy of the data, staff from the University of Michigan 
perform annual on-site audits of all participating hospitals.  
 PICCs are defined as vascular access devices inserted in veins of the 
upper extremity that terminate at the cavoatrial junction; thus, midlines, central 
venous catheters or catheters placed in lower extremity veins are excluded. 
However, the presence of a central venous catheter (e.g., “triple lumen catheter”) 
in a limb or neck at the time of PICC insertion is captured. Data regarding PICC 
characteristics (e.g., gauge, lumens, tip position verification) and indication for 
PICC placement are obtained directly from vascular nursing or interventional 
radiology insertion notes or physician order for PICC placement. For this 
analysis, data from patients enrolled in the study between January 2nd, 2014 and 
June 11th
 
, 2016 were included. 
Covariates 
 Detailed medical history including comorbidities, physical findings, 
laboratory and medication data are collected from the medical record. 
Standardized definitions using ICD-9 and Elixhauser criteria were used to define 
comorbidities at hospital admission.[13] Variables including age (<64 versus >65 
years) sex, race, body mass index, tobacco use (never, former, current), principal 
admitting diagnosis, history of upper or lower-extremity DVT (within 30-days, 
beyond 30-days, never), inpatient surgery within 30 days of PICC placement, 
chemotherapy or blood administration during hospitalization, trauma requiring 
hospitalization within 30 days, immobilizing plaster cast at the time of PICC 
placement, hip or knee replacement within 30 days of PICC placement, presence 
of active infection, existing central venous catheter when PICC was placed 
(yes/no), diabetes mellitus (uncomplicated vs complicated by micro- or 
macrovascular complications), history of cerebrovascular accident or transient 
ischemic attack, history of myocardial infarction, sickle cell disease, venous 
thromboembolism prophylaxis (i.e., receipt of subcutaneous heparin twice or 
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thrice daily regimens or use of enoxaparin at prophylactic doses), receipt of 
treatment dose anticoagulation for any reason, aspirin, statin, erythropoiesis 
stimulating agents, and antiplatelet medication administration are also abstracted 
directly from medical records. Active cancer was defined as admission for a 
cancer diagnosis or for chemotherapy. Serious lung disease was defined as 
receipt of invasive or non-invasive ventilatory support during hospitalization. Life-
threatening illness was defined as any condition which either required ICU 
admission or transfer during hospitalization. Laboratory values including white 
blood cell (WBC) count (above or below 12,000 as this is the cut-off between 
abnormal and normal for most laboratories in the United States), hemoglobin, 
platelet count and international normalized ratio (INR) at the time of PICC 
placement are collected. 
 
Ascertainment of Outcomes   
 The primary outcome was radiographically-confirmed upper-extremity 
DVT (defined as presence of a report in the patients medical record showing a 
compression or duplex ultrasound with visible thrombus, non-compressibility of 
the vein or computed tomography with similar positive findings) following PICC 
placement. At all sites, testing for DVT occurs only in the presence of clinical 
symptoms (e.g., arm pain, swelling). Patients with suspected DVT without 
confirmatory imaging findings or patients with documented pulmonary embolism 
but absence of a confirmed upper-extremity DVT were excluded.  
 
Statistical Analyses 
 Putative risk factors associated with PICC-related thrombosis were 
assessed according to a previously published[14] and validated conceptual 
model for PICC complications.[15, 16] In accordance with this framework, 
covariates associated with PICC-DVT were first summarized as patient-, 
provider- and device-factors using descriptive variables. Unadjusted associations 
of covariates with the probability of PICC-DVT were initially assessed with results 
expressed as odds ratios (OR) and 95% confidence intervals (CI). The amount of 
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missing data among the covariates considered was small (16 covariates 
contained some amount of missing data, with an average of 6% of values 
missing per variable). These missing data were imputed through a 10-fold 
multiple imputation procedure.[17] 
 The Michigan Risk Score was developed in accordance with validated risk 
assessment tools,[18-20] with validation of the final model performed using 
methodologic standards for prediction rules.[21, 22]  Both a Cox-proportional 
hazards model for time to PICC-DVT and a logistic mixed model were 
considered. As the predictive performance of the Cox model (as measured by the 
time-dependent ROC), was not superior to that of the logistic model and did not 
vary substantially over time, the simpler logistic model was chosen. Baseline 
covariates with an unadjusted p-value ≤0.10 in logistic mixed effect models with 
hospital specific random intercepts were considered as candidate predictors in a 
multivariable model. In keeping with recommended approaches,[23]  all 
candidate predictors were entered into the model, with the final multivariable 
model determined by a stepwise selection procedure based on covariate 
contributions to the model fit, as measured by the Schwarz criterion.[24] In order 
to obtain the most parsimonious model, covariates selected were examined in 
the mixed effects model for their individual contribution to predictive performance, 
as determined by significance tests across competing model AUC values.[25]  
 Coefficients derived from the final model were assigned integer point 
values such that a total point score was calculated for each patient. The number 
of points assigned were based on the regression coefficient (rounding up to the 
closest whole integer) or what would be easiest for clinicians to recall (e.g., 2 
points for double-lumen PICCs vs. 3-points for triple lumen devices) if the 
coefficients were similar. With respect to history of VTE, we divided this into 
categories: events within 30-days vs. events beyond 30-days. The rationale for 
this split relates to the fact (a) the risk of VTE is greatest in the period most 
proximal to an event,[26, 27] and (b) PICCs are often inappropriately removed 
and replaced in the setting of thrombosis typically within this 30-day window [3] 
[28]. Based on this score, patients were assigned to risk class I,II, III, or IV. The 
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number of risk classes and the cutoff values for each class were selected so as 
to (a) maximize the AUC with respect to the classification rule and (b) maintain 
increasing DVT rates in the empirical distribution with respect to each class. 
The predictive performance of the model was assessed using several 
approaches. To assess calibration, a logistic mixed-effect model with risk class 
as a categorical predictor was used to determine the predicted VTE rate within 
each risk group. Marginal predicted event rates and discrimination were 
determined by integrating over the distribution of the random effects.[29] 
Additionally, a bootstrap internal validation procedure with 200 bootstrap 
resamples was performed to determine the calibration intercept, slope and the 
estimated optimism of discrimination.[30, 31]  
A two-sided p-value of less than 0.05 was used to indicate significance in 
all analyses. All analyses were performed in SAS, version 9.4 (SAS Institute Inc., 
Cary, NC) and R version 3.2.4.   
 
Ethical and Regulatory Oversight 
 The University of Michigan Medical School’s Institutional Review Board 
reviewed this study and it received a “Not Regulated” status. 
 
RESULTS 
Patient Characteristics and Outcomes 
 Of 23,010 patients that received PICCs, 475 (2.1%) developed 
symptomatic, image-confirmed PICC-DVT (Figure 1). Of these 475 patients, 19 
(4.0%) died during the follow-up period whereas of the 22,535 patients without 
PICC-DVT, 1,173 (5.2%) died during follow-up. Patients who developed PICC-
DVT were similar to those that did not with respect to demographics such as age, 
gender, and race. However, differences in comorbidities between the two groups 
on bivariate, unadjusted comparisons were noted. For example, patients with 
PICC-DVT more often had active cancer (11.6% vs. 6.1%, p<0.01), history of 
cancer (28.0% vs. 23.4%, p=0.02), and history of prior DVT (23.8% vs. 13.6%, 
p<0.01). Patients with PICC-DVT also were more likely to receive their PICC in 
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an ICU-setting compared with those without PICC-DVT (43.7% vs. 31.9%, 
p<0.01). Accordingly, indications for PICC placement differed between groups. 
For example, patients with PICC-DVT more frequently had PICCs placed for 
chemotherapy (4.6% vs. 2.6%, p<0.01) or difficult intravenous access (24.8% vs. 
21.1%, p=0.05) vs. those without. 
With respect to device characteristics, no significant difference in the 
number of insertion attempts or arm of PICC insertion between those that did vs. 
did not develop PICC-DVT was observed. Notably, patients that received 
antimicrobial-coated PICCs experienced higher rates of thrombosis than those 
that received non-coated devices (12.8% vs. 6.9%, p<0.01) (Table 1). 
Associations between patient-, provider- and device-characteristics and 
PICC-DVT are shown in Table 2, accounting for hospital level clustering. Several 
patient characteristics including active cancer and history of cancer (OR=2.10 
[95%CI=1.57-2.82] and OR=1.27 [95%CI=1.04-1.56], respectively), history of 
DVT within 30-days of PICC placement (OR=2.46 [95%CI=1.69-3.57]), and 
critical illness (OR=1.60 [95%CI=1.33-1.94]) were significantly associated with 
thrombosis. Thus, PICCs placed for chemotherapy (OR=1.98 [95%CI=1.27-
3.10]), total parenteral nutrition (OR=1.73 [95%CI=1.23-2.44]), and difficult 
intravenous access (OR=1.31 [95%CI=1.05-1.64]) were also associated with 
thrombosis.  
 
Multivariable Models and Risk Score 
Five factors emerged as being significantly associated with PICC-DVT: 
history of upper or lower-extremity DVT, number of PICC lumens, WBC 
count>12,000, active cancer and presence of another CVC. Of the 23,010 
patients, 23.4% (n=5,377) had none of these risk factors and were assigned to 
risk class I (i.e., lowest risk of thrombosis). The overall rate of PICC-DVT in this 
group was 0.9% (n=47). In contrast, the remaining 76.6% (n=17,633) of patients 
with one or more of the above factors experienced over a 2-fold increase in 
PICC-DVT (2.4%, n=428).  
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To create the Michigan Risk Score, we assigned points to each of the five 
factors based on their regression coefficients. Patients were assigned to risk 
classes based on cumulative point totals (Table 3). Observed DVT rates were 
0.9% for risk class I, 1.6% for class II, 2.9% for class III and 6.9% for class IV, 
with marginal predicted probabilities of 0.9% (0.7, 1.2), 1.5% (1.2, 1.9), 2.6% 
(2.2, 3.0) and 4.5% (3.7, 5.4) for classes I, II, III, IV and V, respectively. In a 
logistic mixed-effects regression model with risk class as a categorical predictor, 
the risk classification rule was significantly associated with PICC-DVT 
(p<0.0001), with odds ratios of 1.68 (95 % CI: 1.19, 2.37), 2.90 (95 % CI: 2.09, 
4.01) and 5.20 (95 % CI: 3.65, 7.42) for risk classes II, III and IV vs. risk class I, 
respectively (Table 4).  
Internal validation of the Michigan Risk Score was performed using 
bootstrap resampling. The calibration intercept and slope were calculated to be -
0.35 (95% CI: -0.78, 0.56) and 0.90 (95% CI: 0.78, 1.14), respectively. The area 
under the receiver-operating-characteristics curve in the derivation data from the 
logistic mixed model and from the marginal predicted probabilities were 0.71 
(estimated optimism of 0.04) and 0.65 (estimated optimism of 0.03), respectively.  
The predictive performance of the model was unchanged by accounting for the 
ICU status of patients, with AUC values of 0.71 and 0.65 from the logistic mixed 
model and marginal predicted probabilities, respectively. 
 
DISCUSSION 
 Although increasingly used in clinical practice and safer to insert than 
traditional central venous catheters, accumulating evidence suggests that PICCs 
are associated with risk of thrombosis.[5, 6, 9] Despite growing recognition of this 
phenomenon, clinicians to date have had no way to identify patients that might 
be at untoward risk of DVT when considering PICC placement. To bridge this 
gap, we used data from medical records and contemporary modeling techniques 
to identify risk-factors associated with PICC-DVT. These factors included: history 
of DVT, active cancer, the number of PICC lumens, white cell count >12,000 at 
the time of PICC insertion and presence of another CVC. The Michigan Risk 
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Score accurately distinguished those at low vs. high-risk, with a 5-fold greater 
risk of thrombosis for those in the highest risk class compared with the lowest 
risk class. This scoring system is a potentially useful tool in informing risk of, and 
targeting potential prevention efforts, at thrombosis associated with PICCs. 
 Some predictors of PICC-DVT identified in our study are similar to those 
reported by other investigators. For instance, Evans and colleagues found that 
increasing catheter gauge (and resultant increase in lumens) was associated 
with thrombosis such that efforts to decrease PICC diameter led to reduction in 
DVT.[32, 33] Similarly, the PADUA risk score (widely used to estimate risk of 
VTE in hospitalized patients), heavily weighs active cancer and history of 
thrombosis when estimating risk of thrombosis.[34] Our work builds on the work 
of these groups and further advances the field by: (a) focusing specifically on 
PICCs; (b) distinguishing the contribution of increasing lumens with respect to 
risk of DVT; and (c), distinguishing the greater importance of recent thrombosis 
(<30 days) from a remote history of the same. Additionally, we found that 
elevated white count during PICC insertion and presence of another central 
venous catheter when a PICC was placed were also predictive of thrombosis. 
Interestingly, most patients with another central venous catheter needing PICC 
placement anecdotally did so not for clinical reasons (e.g., need for greater 
vascular access), but rather as a transition strategy to leave the ICU or mitigate 
risk of CLABSI with a device that has dwelled for ten or more days. Changing 
central venous catheters has not been shown to reduce the risk of CLABSI in 
prior studies,[35] and is not recommended by current guidelines.[36] Our data 
suggest, rather, that such practice and transitioning to PICCs is associated with 
increased risk of thrombosis. These findings have not been previously reported 
and have important clinical implications. For instance, avoiding PICC insertion in 
patients with another central venous catheter simply because they are leaving 
the ICU and/or deferring placement vs. considering an alternative device in 
patients with elevated WBC counts are clinically salient strategies that might 
reduce thrombosis and improve patient safety.  
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 Our study has limitations. First, although we used several approaches to 
examine the performance of the Michigan Risk Score, external validation was not 
performed and is necessary before widespread use can be recommended. 
Relatedly, we used many covariates when fitting our model, which may have 
inadvertently led to model overfitting since we use a single dataset for derivation 
and validation. However, because we followed published and recommended 
approaches for developing the MRS,[30, 37] we believe the likelihood of this 
possibility is low. Second, the HMS consortium is focused purely on medical 
patients and samples from within a larger population. While we include patients 
with cancer and those that are critically ill, lack of inclusion of other patient 
groups at high-risk of thrombosis (e.g., surgical patients) and inclusion of a 
universal population may limit generalizability of the tool. Third, data used to 
develop this tool was collected through review of medical records and, as such, 
is susceptible to reporting bias.  
 Our study also has important strengths. First, we have created a novel risk 
tool with which to estimate the risk of PICC-DVT. Given the growing use of 
PICCs and lack of risk models to examine risk of thrombosis from these devices, 
the Michigan Risk Score represents an important contribution to the literature. 
Second, we expect that this tool will prove useful in helping inform the decision 
as to whether use of a PICC is appropriate and safe for a given patient. With the 
introduction of appropriateness criteria to guide the use of PICCs,[38] the 
Michigan Risk Score adds to a growing body of knowledge that helps improve 
decision-making related to this device. Third, much as has been the case with 
other risk tools for venous thromboembolism,[39-41] we expect that this score 
may prove useful in informing certain aspects of PICC care, such as the utility of 
diagnostic imaging when considering thrombosis (e.g., avoidance in low-risk 
patients) as well as the benefit of prolonged anticoagulation following confirmed 
thrombosis (extended use in high-risk categories). While studies that test the 
usefulness of our tool for these issues are necessary, these are important clinical 
questions that the Michigan Risk Score may help inform. Finally, we have begun 
to explore methods for implementation to bring this tool to clinicians at the 
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bedside. Given the proliferation of smartphones and apps, one approach is an 
online, web-based risk-calculator that could facilitate point-of-care estimation of 
risk of thrombosis before placing a PICC. A demo version of this tool has been 
created and highlights how this model may prove extremely useful when making 
clinical decisions related to PICCs (Figure 2). 
 In conclusion, we developed and internally validated the Michigan Risk 
Score to predict PICC-DVT. External validation of the score, followed by 
strategies to implement and evaluate the tool in clinical settings would be 
welcomed. 
 
ADDENDUM 
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Table 1. General Characteristics of Patients with and without PICC-VTE (n=23,010) 
Category/Variable Modifier No DVT (n=22,535) Confirmed DVT 
(n=475) 
p 
Patient Characteristics 
Male Gender  11063 (49.1%) 242 (50.9%) 0.43 
Race White 16703 (76.0%) 335 (73.0%) 0.13 
 Other 5269 (24.0%) 124 (27.0%)  
Age group >65 years 11088 (49.2%) 234 (49.3%) 0.98 
 <64 years 11447 (50.8%) 241 (50.7%)  
Body Mass Index (BMI) Median (IQR) 28.76 (23.96-35.31) 27.58 (23.49-
33.70) 
0.02 
Hyperlipidemiaa   8308 (36.9%) 171 (36.0%) 0.70 
Hypertension a  15416 (68.4%) 321 (67.6%) 0.70 
Myocardial Infarctionb  937 (4.2%) 20 (4.2%) 0.95 
Congestive Heart Failureb  3200 (14.2%) 53 (11.2%) 0.06 
Peripheral vascular disordersa  3453 (15.3%) 57 (12.0%) 0.05 
Cerebrovascular diseasea  3414 (15.1%) 74 (15.6%) 0.80 
Dementiaa  1930 (8.6%) 38 (8.0%) 0.66 
COPDb  2243 (10.0%) 46 (9.7%) 0.85 
Rheumatoid arthritisb  238 (1.1%) 8 (1.7%) 0.19 
Peptic Ulcer Diseasea  856 (3.8%) 25 (5.3%) 0.10 
Diabetes without complicationsa  4621 (20.5%) 88 (18.5%) 0.29 
Diabetes with complicationsa  4430 (19.7%) 89 (18.7%) 0.62 
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Renal Failurea  7834 (34.8%) 149 (31.4%) 0.12 
Kidney transplant  131 (0.6%) 3 (0.6%) 0.89 
Hemodialysisa  765 (3.4%) 24 (5.1%) 0.05 
Peritoneal Dialysisa  42 (0.2%) 0 (0.0%) 0.35 
Hemi- or paraplegiab  1075 (4.8%) 27 (5.7%) 0.36 
Mild liver diseasea  1483 (6.6%) 24 (5.1%) 0.18 
Moderate to severe liver diseasea  863 (3.8%) 13 (2.7%) 0.22 
Known HIV or AIDSa  161 (0.7%) 1 (0.2%) 0.19 
History of Cancer  5271 (23.4%) 133 (28.0%) 0.02 
Active cancer  1376 (6.1%) 55 (11.6%) <0.01 
Coagulopathya  791 (3.5%) 27 (5.7%) 0.01 
Charlson/Deyo Comorbidity Index Median (IQR) 3 (1-5) 3 (1-5) 0.08 
History of CLABSI  269 (1.2%) 8 (1.7%) 0.33 
History of DVT Within 30 days 643 (2.9%) 32 (6.7%) <0.01 
 Prior history 2414 (10.7%) 81 (17.1%)  
History of PE Within 30 days 348 (1.5%) 6 (1.3%) <0.01 
 Positive history 1289 (5.7%) 42 (8.8%)  
History of any VTE Event Within 30 days 874 (3.9%) 36 (7.6%) <0.01 
 Positive history 2886 (12.8%) 94 (19.8%)  
Inflammatory Bowel Diseaseb  261 (1.2%) 13 (2.7%) <0.01 
Serious lung diseaseb  6915 (30.7%) 189 (39.8%) <0.01 
Life-threatening illnessb  6990 (31.0%) 201 (42.3%) <0.01 
Pneumoniab  4763 (21.1%) 116 (24.4%) 0.08 
Sepsisb  7241 (32.1%) 161 (33.9%) 0.42 
History of Prior CVA/TIA  3843 (17.1%) 79 (16.6%) 0.81 
Venous stasisa  1476 (6.5%) 22 (4.6%) 0.09 
Smoking Status Current/ 
Former 
13037 (57.9%) 276 (58.1%) 0.91 
 Never 9498 (42.2%) 199 (41.9%)  
Statin   8034 (35.7%) 154 (32.4%) 0.15 
Aspirin  7190 (31.9%) 118 (24.8%) <0.01 
Other antiplatelet therapy  3068 (13.6%) 52 (10.9%) 0.09 
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White Blood Cell Counta Median (IQR) 9.20 (6.70-12.80) 10.40 (7.20-
14.90) 
<0.01 
Hemoglobina Median (IQR) 10.20 (8.80-11.70) 9.80 (8.60-11.50) <0.01 
Platelet Counta Median (IQR) 226.00 (160.00-
309.00) 
228.50 (144.00-
312.00) 
0.37 
International Normalized Ratio 
(INR)a 
Median (IQR) 1.15 (1.02-1.39) 1.19 (1.08-1.34) 0.29 
eGFR categorya <15 610 (3.8%) 17 (5.1%) 0.39 
 15-29 1295 (8.0%) 26 (7.8%)  
 30-44 1724 (10.6%) 26 (7.8%)  
 45-59 2170 (13.4%) 45 (13.5%)  
 >60 10414 (64.2%) 219 (65.8%)  
Hospital LOS prior to PICC 
placement (days) 
Median (IQR) 4 (2-7) 4 (2-8) 0.09 
CVC or PICC  in prior 6 months 4900 (21.7%) 138 (29.1%) <0.01 
Presence of another CVC  3206 (14.2%) 109 (22.9%) <0.01 
Provider Characteristics 
Operator Type Vascular 
Access Nurse 
15079 (66.9%) 286 (60.2%) <0.01 
 Interventional 
Radiologist 
4535 (20.1%) 120 (25.3%)  
 Physician 237 (1.1%) 3 (0.6%)  
 Other    
Documented Indication for PICC 
Placement 
Antibiotic 
therapy 
8633 (38.3%) 137 (28.8%) <0.01 
 Chemotherapy 580 (2.6%) 22 (4.6%) <0.01 
 Difficult IV 
access 
4763 (21.1%) 118 (24.8%) 0.05 
 Medications 
requiring 
central venous 
access 
2691 (11.9%) 52 (10.9%) 0.51 Au
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 Incompatible 
IV 
fluids/medicati
on 
345 (1.5%) 8 (1.7%) 0.79 
 TPN 1171 (5.2%) 38 (8.0%) <0.01 
 Unknown 7314 (32.5%) 159 (33.5%) 0.64 
Location of PICC Insertion Outpatient 93 (0.4%) 0 (0.0%) <0.01 
 Emergency 
Room 
385 (1.8%) 11 (2.5%)  
 ICU 6828 (31.9%) 194 (43.7%)  
 General Floor 14114 (65.9%) 239 (53.8%)  
Placement attempts >1 2552 (11.5%) 47 (10.1%) 0.32 
Arm selected for insertion Right Arm 15814 (70.2%) 327 (68.8%) 0.51 
Vein selected for insertion Basilic 13710 (60.8%) 275 (57.9%) 0.03 
 Brachial 6912 (30.7%) 169 (35.6%)  
 Cephalic 1165 (5.2%) 14 (2.9%)  
 Other 748 (3.3%) 17 (3.6%)  
Device characteristics     
PICC dwell time (days) Median (IQR) 12 (6-25) 12 (7-22) 0.44 
PICC Gauge 4 French 6729 (31.7%) 92 (20.0%) <0.01 
 5 French 12691 (59.7%) 312 (68.0%)  
 > 6 French 1822 (8.9%) 55 (12.0%)  
Power PICC  20433 (90.7%) 422 (88.8%) 0.18 
Antimicrobial coating  1556 (6.9%) 61 (12.8%) <0.01 
Anti-thrombotic coating  385 (1.7%) 9 (1.9%) 0.76 
Valved PICC  5589 (24.8%) 102 (21.5%) 0.10 
Number of PICC lumens Single 8481 (37.7%) 105 (22.1%) <0.01 
 Double 10886 (48.4%) 277 (58.3%)  
 Triple/Quad 3121 (13.9%) 93 (19.6%)  
aat time of PICC placement; b
 
within previous 30 days;  
Legend: IQR=interquartile range;  COPD=chronic obstructive pulmonary disease; HIV=human 
immunodeficiency virus; AIDS=acquired immune deficiency syndrome; CLABSI=central line-associated 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
bloodstream infection; DVT=deep vein thrombosis; PE=pulmonary embolism; VTE=venous 
thromboembolism; CVA=cerebrovascular accident; TIA=transient ischemic attack; eGFR=estimated 
glomerular filtration rate; LOS=length of stay; CVC=central venous catheter; PICC=peripherally inserted 
central catheter; TPN=total parenteral nutrition; ICU=intensive care unit. 
 
Definitions:
 
 Diabetes without complications = diabetes without documented retinopathy, nephropathy, 
neuropathy, cardio- or cerebrovascular events. 
 
 
 
Table 2. Univariate associations between Patient-, Provider- and Device-factors and Risk of 
PICC VTE (Logistic mixed effect model) 
Category/Variable Comparator / Referent Group Odds Ratio [OR] 
95% Confidence 
Interval [CI] 
p 
Patient Characteristics     
Male Gender  1.10 (0.91, 1.32) 0.32 
Race White vs. Other 0.97 (0.77, 1.21) 0.76 
Age group >65 vs. <64 1.05 (0.88, 1.27) 0.57 
Body Mass Index (BMI) Per unit increase 0.99 (0.98, 1.00) 0.02 
Hyperlipidemia Yes vs. No 1.03 (0.84, 1.25) 0.80 
Hypertension Yes vs. No 0.99 (0.81, 1.20) 0.89 
Myocardial Infarction Yes vs. No 1.04 (0.66, 1.65) 0.86 
Congestive Heart Failure Yes vs. No 0.71 (0.53, 0.96) 0.02 
Peripheral vascular disorders Yes vs. No 0.78 (0.59, 1.04) 0.09 
Cerebrovascular disease Yes vs. No 1.04 (0.81, 1.34) 0.76 
Dementia Yes vs. No 0.97 (0.69, 1.37) 0.88 
COPD Yes vs. No 0.95 (0.70, 1.30) 0.76 
Rheumatoid arthritis Yes vs. No 1.38 (0.67, 2.82) 0.38 
Peptic Ulcer Disease Yes vs. No 1.44 (0.95, 2.17) 0.09 
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Diabetes without complications Yes vs. No 0.89 (0.70, 1.12) 0.32 
Diabetes with complications Yes vs. No 0.95 (0.75, 1.21) 0.69 
Renal Failure Yes vs. No 0.89 (0.73, 1.09) 0.25 
Kidney transplant Yes vs. No 1.01 (0.32, 3.21) 0.98 
Hemodialysis Yes vs. No 1.32 (0.86, 2.01) 0.20 
Hemi/paraplegia Yes vs. No 1.23 (0.83, 1.82) 0.31 
Mild liver disease Yes vs. No 0.74 (0.49, 1.12) 0.15 
Moderate/severe liver disease Yes vs. No 0.66 (0.38, 1.15) 0.14 
Known HIV/AIDS Yes vs. No 0.29 (0.04, 2.05) 0.21 
History of Cancer Yes vs. No 1.27 (1.04, 1.56) 0.02 
Active cancer Yes vs. No 2.10 (1.57, 2.82) <0.01 
Coagulopathy Yes vs. No 1.45 (0.97, 2.18) 0.07 
Charlson/Deyo comorbidity 
index 
Per unit increase 0.97 (0.94, 1.01) 0.15 
History of Prior CLABSI Yes vs. No 1.36 (0.67, 2.78) 0.39 
History of Prior DVT Within 30 days vs. Never 2.46 (1.69, 3.57) <0.01 
 Positive history vs. Never 1.57 (1.13, 2.17)  
History of Pulmonary Embolism Within previous 30 days vs. Never 0.84 (0.37, 1.89) 0.02 
 Positive history vs. Never 1.57 (1.13, 2.17)  
History of Any VTE Event Within previous 30 days vs. Never 2.11 (1.48, 3.00) <0.01 
 Positive history vs. Never 1.74 (1.38, 2.20)  
Inflammatory Bowel Disease Yes vs. No 2.18 (1.24, 3.86) <0.01 
Serious lung disease Yes vs. No 1.59 (1.31, 1.94) <0.01 
Life-threatening illness Yes vs. No 1.60 (1.33, 1.94) <0.01 
Pneumonia Yes vs. No 1.21 (0.98, 1.50) 0.08 
Sepsis Yes vs. No 1.15 (0.95, 1.41) 0.16 
History of Prior CVA/TIA Yes vs. No 0.97 (0.76, 1.24) 0.79 
Venous stasis Yes vs. No 0.70 (0.46, 1.09) 0.11 
Smoking status Current/former vs. Never 1.01 (0.84, 1.22) 0.89 
Statin Yes vs. No 0.89 (0.73, 1.08) 0.23 
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Aspirin Yes vs. No 0.73 (0.59, 0.90) <0.01 
Other antiplatelet therapy Yes vs. No 0.77 (0.57, 1.03) 0.08 
White Blood Cell Count Per unit increase 1.01 (1.00, 1.01) <0.01 
Hemoglobin Per unit increase 0.96 (0.92, 1.00) 0.06 
Platelet Count Per unit increase 1.00 (1.00, 1.00) 0.41 
International Normalized Ratio Per unit increase 1.00 (1.00, 1.00) 0.95 
eGFR category >=60 vs. <15 0.87 (0.48, 1.59) 0.63 
 45-59 vs. <15 0.71 (0.37, 1.39)  
 30-44 vs. <15 0.97 (0.55, 1.73)  
 15-29 vs. <15 0.98 (0.60, 1.60)  
Hospital LOS prior to PICC 
placement 
Per unit increase 1.01 (1.00, 1.03) 0.05 
CVC or PICC Yes vs. No in prior 6 months 1.40 (1.14, 1.72) <0.01 
Existing CVC at time of PICC 
placement 
Yes vs. No 1.74 (1.40, 2.17) <0.01 
Provider Characteristics    
Documented Indication for 
PICC Placement 
Antibiotic Therapy 0.73 (0.59, 0.91) <0.01 
 Chemotherapy 1.98 (1.27, 3.10) <0.01 
 Difficult IV Access 1.31 (1.05, 1.64) 0.02 
 Medications requiring central venous 
access 
1.12 (0.82, 1.54) 0.47 
 Incompatible IV fluids/medications 1.21 (0.59, 2.47) 0.61 
 TPN 1.73 (1.23, 2.44) <0.01 
 Other / Unknown 0.82 (0.67, 1.02) 0.07 
Location of PICC Insertion ICU vs. General Medical Ward 1.68 (1.39, 2.03) <0.01 
 ER vs. General Medical Ward 1.69 (0.91, 3.1)  
Placement attempts >1 vs. 1 0.92 (0.68, 1.26) 0.62 
Arm selected for insertion Right vs. Left 0.87 (0.71, 1.07) 0.18 
Vein selected for insertion Other vs. Basilic 1.15 (0.69, 1.91) 0.06 
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 Cephalic vs. Basilic 0.66 (0.38, 1.13)  
 Brachial vs. Basilic 1.23 (1.01, 1.51)  
Device characteristics    
PICC dwell time (days) Per unit increase 1.00 (0.99, 1.00) 0.16 
Gauge Per unit increase 1.57 (1.33, 1.86) <0.01 
PICC length Per unit increase 1.00 (0.98, 1.02) 0.87 
Power PICC Yes vs. No 0.88 (0.60, 1.29) 0.51 
Antimicrobial coated Yes vs. No 1.16 (0.82, 1.63) 0.40 
Anti-thrombotic coated Yes vs. No 0.84 (0.41, 1.71) 0.63 
Valved PICC Yes vs. No 0.86 (0.64, 1.17) 0.34 
Number of PICC lumens Triple/Quad vs. Single 2.49 (1.84, 3.37) <0.01 
 Double vs. Single 1.88 (1.49, 2.38)  
Legend
 
: COPD=chronic obstructive pulmonary disease; HIV=human immunodeficiency virus; 
AIDS=acquired immune deficiency syndrome; CLABSI=central line-associated bloodstream infection; 
DVT=deep vein thrombosis; PE=pulmonary embolism; VTE=venous thromboembolism; 
CVA=cerebrovascular accident; TIA=transient ischemic attack; eGFR=estimated glomerular filtration rate; 
LOS=length of stay; CVC=central venous catheter; PICC=peripherally inserted central catheter; TPN=total 
parenteral nutrition; ICU=intensive care unit;  
 
 
 
 
Table 3. Michigan Risk Score for PICC Thrombosis (Stage 2 Multivariable Logistic 
mixed model) 
Predictor Variable Status Odds Ratio (95% CI) Points p 
Presence of another 
CVC when index PICC 
placed 
Yes vs. No 1.43 (1.14, 1.79) 1 0.0022 Au
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Predictor Variable Status Odds Ratio (95% CI) Points p 
WBC Count at Time of 
PICC Insertion 
>12 vs. <12 1.46 (1.20, 1.77) 1 0.0001 
Active cancer Yes vs. No 1.97 (1.47, 2.65) 2 <0.0001 
Number of PICC 
Lumens 
Double vs. Single 1.63 (1.28, 2.07) 2 0.0025 
Triple/Quad vs. Single 1.98 (1.45, 2.71) 3  
History of Venous 
Thromboembolism 
Yes vs. Never 1.89 (1.47, 2.42) 2 <0.0001 
Within 30 days vs. Never 2.19 (1.50, 3.18) 3  
 
Legend
 
: CI=confidence interval; OR=odds ratio; PICC=peripherally inserted central catheter; 
CVC=central venous catheter 
 
 
 
Table 4. Frequency and Rate of PICC DVT by Michigan Risk Score Class 
Risk Group / Class 
(Total Points) 
Observed Events 
 
Expected Events 
Patients (N) VTE 
(N, %) 
Risk of VTE 
OR (95% CI) 
Probability of VTE 
% (95%CI) 
Class I (0 points) 5377 47 (0.9%) Referent 0.9% (0.7, 1.2) 
Class II (1-2 point) 7808 122 (1.6%) 1.68 (1.19, 2.37) 1.5% (1.2, 1.9) 
Class III (3-4 points) 7597 202 (2.7%) 2.90 (2.09, 4.01) 2.6% (2.2, 3.0) 
Class IV (>4 points) 2228 104 (4.7%) 5.20 (3.65, 7.42) 4.5% (3.7, 5.4) 
 
Legend
 
: VTE=venous thromboembolism CI=confidence interval; PICC=peripherally inserted 
central catheter; CVC=central venous catheter 
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Figure 1. Study Flow Diagram 
 
Figure 2. Screenshots of Risk Calculator 
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